ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 161 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2018. The put-call ratio across all filers is 3.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $224,000 | +0.9% | 4,874 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $222,000 | +31.4% | 4,999 | +16.1% | 0.00% | +50.0% |
| Q2 2018 | $169,000 | -45.7% | 4,304 | 0.0% | 0.00% | -60.0% |
| Q1 2018 | $311,000 | +6.5% | 4,304 | -2.9% | 0.01% | +25.0% |
| Q4 2017 | $292,000 | +16.3% | 4,433 | -11.6% | 0.00% | 0.0% |
| Q3 2017 | $251,000 | +27.4% | 5,012 | +18.0% | 0.00% | +33.3% |
| Q2 2017 | $197,000 | +21.6% | 4,247 | -7.7% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | -38.4% | 4,600 | -75.8% | 0.00% | -40.0% |
| Q3 2016 | $263,000 | +39.9% | 19,000 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $188,000 | -41.4% | 19,000 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $321,000 | -24.1% | 19,000 | 0.0% | 0.01% | -14.3% |
| Q4 2015 | $423,000 | +122.6% | 19,000 | +136.3% | 0.01% | +133.3% |
| Q3 2015 | $190,000 | -85.3% | 8,040 | -49.1% | 0.00% | -66.7% |
| Q2 2015 | $1,292,000 | – | 15,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |